EMA Paediatric Committee Endorses Cynata’s CYP-001 Trial Plan for aGvHD
Cynata Therapeutics secures a crucial regulatory green light from the EMA’s Paediatric Committee for its CYP-001 treatment in children with acute graft versus host disease, paving the way for sequential adult and paediatric trials in Europe.
- EMA PDCO grants Positive Opinion on CYP-001 paediatric plan
- Phase 2/3 trial planned for children post adult Phase 3 study
- Phase 2 adult trial results due mid-2026 underpin next steps
- aGvHD remains a critical unmet need with limited treatment options
- CYP-001 showed promising Phase 1 safety and efficacy signals
EMA Paediatric Committee Approves CYP-001 Development Plan
Cynata Therapeutics (ASX:CYP) has achieved a significant regulatory milestone with the European Medicines Agency’s Paediatric Committee (PDCO) issuing a Positive Opinion on its Paediatric Investigation Plan (PIP) for CYP-001. This approval is a prerequisite for launching a Phase 3 clinical trial in the European Union, covering patients from infants to adolescents suffering from acute graft versus host disease (aGvHD).
The PDCO’s endorsement covers a combined Phase 2/3 randomised controlled trial involving approximately 72 paediatric patients aged 28 days to 18 years. This trial is set to follow an initial adult Phase 3 study, with Cynata planning to start the paediatric trial only after the adult data’s primary analysis is complete. Notably, the regulatory framework allows Cynata to submit a Marketing Authorisation Application for adults while the paediatric trial continues.
Clinical Progress and Trial Design
CYP-001 is Cynata’s proprietary Cymerus™-derived mesenchymal stem cell therapy designed to modulate immune responses in aGvHD, a severe complication of bone marrow transplantation. The condition affects up to half of transplant recipients and carries a grim prognosis, especially in steroid-resistant cases where historical two-year survival is below 20%.
The drug’s potential was highlighted by a Phase 1 adult trial showing an 87% overall response rate and 60% two-year survival without serious safety concerns. Currently, Cynata has completed enrolment and the primary evaluation period for its pivotal Phase 2 adult trial, with 65 participants across Australia, the US, and Europe. Results from this trial, which randomises patients to steroids plus CYP-001 or placebo, are expected in late June or early July 2026 and will be critical to advancing to the Phase 3 stage.
European Market Opportunity and Strategic Implications
Europe represents a particularly important market for Cynata, with aGvHD incidence roughly double that of the US. The absence of any EMA-approved cell-based therapies for aGvHD in any age group underscores the unmet medical need. Nuket Desem, Cynata’s Director of Regulatory and Scientific Affairs, emphasised the importance of this approval for progressing late-phase clinical development and eventual commercialisation in the EU.
With the PDCO’s Positive Opinion now forwarded to the European Commission for formal adoption, Cynata is positioned to advance its clinical program in line with regulatory expectations. This regulatory nod also aligns with the company’s recent capital raise to extend its cash runway ahead of key data readouts, underscoring a critical juncture in its development timeline.
Bottom Line?
The EMA’s paediatric trial endorsement clears a regulatory hurdle, but Cynata’s next big test remains the imminent Phase 2 adult trial results that will dictate the pace of CYP-001’s clinical and commercial journey in Europe.
Questions in the middle?
- Will the Phase 2 adult trial data validate CYP-001’s efficacy to support Phase 3 progression?
- How will Cynata navigate market access and reimbursement challenges for aGvHD therapies in Europe?
- What timeline can investors expect for EMA formal adoption of the PIP and subsequent trial commencements?
